Dr. Ben Park on ctDNA: Precision Oncology in Breast Cancer at SABCS 2024

6 Views

  • Thanks! Share it with your friends!

    You disliked this video. Thanks for the feedback!

admin
Published
Discover the evolving role of circulating tumor DNA (ctDNA) in breast cancer care with insights from Dr. Ben Park, Professor of Medicine and Director of Precision Oncology at Vanderbilt, at SABCS 2024: https://oncfellows.com/ctdna-in-breast-cancer-sabcs

0:00 Circulating tumor DNA in Breast Cancer
6:20 What do you recommend informing the patient of?
10:10 Key Takeaways

Joined by Dr. Jasmin Hundal, Dr. Park discusses ctDNA’s potential for detecting minimal residual disease (MRD) and predicting recurrence, bridging the gap between clinical validation and utility.

- Understand the biology of ctDNA and its significance in early detection and recurrence prediction.
- Explore ethical considerations and patient conversations around ctDNA testing, including its emotional and financial impact.
- Learn about ongoing trials addressing ctDNA’s clinical utility in improving outcomes for early-stage breast cancer patients.
- Stay ahead in precision oncology by engaging with the latest research and challenges in ctDNA testing.

#BreastCancer #ctDNA #PrecisionOncology #SABCS2024 #MRDDetection #CancerResearch #OncologyInnovation #LiquidBiopsy #DrBenPark
Category
Oncology
Be the first to comment

Up Next